![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » IsoRay Cans GliaSite Due to Low Sales
IsoRay Cans GliaSite Due to Low Sales
![](https://www.fdanews.com/ext/resources/test/Device_Images5/White_Arrow.jpg?t=1474584198&width=430)
April 13, 2016
IsoRay has bid adieu to its GliaSite radiation therapy system and certain ancillary products, following “marginal sales” since its introduction, the company announced in a regulatory filing.
IsoRay has issued notices to end licensing agreements with Dr. Reddy’s Laboratories and Hologic and has slashed a distribution agreement with Karlheinz Goehl-Medizintechnik Goehl.
The system is designed to deliver brachytherapy radiation to treat brain cancer. — Anisa Jibrell
Upcoming Events
-
21Oct